Drug Search Results
More Filters [+]

Proguanil

Alternative Names: proguanil, malarone, malarone pediatric
Latest Update: 2024-05-01
Latest Update Note: Clinical Trial Update

Product Description

Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, Plasmodium falciparum and Plasmodium vivax, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Proguanil)

Mechanisms of Action: DHFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: Malaria | Malaria, Falciparum

Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Oral Ulcer | Pruritus | Anorexia | Asthenia | Diarrhea

Company: Dstl
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Proguanil

Countries in Clinic: United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Malaria

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MMV_SMC_19_02

P1

Completed

Malaria

2022-03-18

Recent News Events